Artur Katz

Summary

Country: Brazil

Publications

  1. pmc Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib
    A Katz
    Centro Paulista de Oncologia and Department of Oncology, Albert Einstein Hospital, Sao Paulo, Brazil
    Br J Cancer 89:S15-8. 2003
  2. ncbi request reprint Primary systemic chemotherapy of invasive lobular carcinoma of the breast
    Artur Katz
    Centro Paulista de Oncologia and Hospital Albert Einstein, Sao Paulo, Brazil
    Lancet Oncol 8:55-62. 2007
  3. doi request reprint Assessment of quality of life in advanced non-small-cell lung cancer: an overview of recent randomized trials
    Everardo D Saad
    Dendrix Research, Sao Paulo, Brazil
    Cancer Treat Rev 38:807-14. 2012
  4. pmc Bevacizumab as first-line therapy in advanced non-small-cell lung cancer: a brazilian center experience
    Denis Leonardo Fontes Jardim
    Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil
    Drugs R D 12:207-16. 2012
  5. ncbi request reprint Trastuzumab: mechanisms of resistance and therapeutic opportunities
    Aknar Calabrich
    Oncology Center, Hospital Sirio Libanes, Sao Paulo, Brazil
    Oncology (Williston Park) 22:1250-8; discussion 1259, 1263. 2008
  6. ncbi request reprint Does neoadjuvant/adjuvant chemotherapy change the natural history of classic invasive lobular carcinoma?
    Artur Katz
    J Clin Oncol 23:6796; author reply 6796-7. 2005

Detail Information

Publications6

  1. pmc Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib
    A Katz
    Centro Paulista de Oncologia and Department of Oncology, Albert Einstein Hospital, Sao Paulo, Brazil
    Br J Cancer 89:S15-8. 2003
    ..Such results call for larger trials designed to evaluate and define the role of gefitinib in the treatment of brain metastases in NSCLC patients, either as a single agent or in combination with radiation therapy...
  2. ncbi request reprint Primary systemic chemotherapy of invasive lobular carcinoma of the breast
    Artur Katz
    Centro Paulista de Oncologia and Hospital Albert Einstein, Sao Paulo, Brazil
    Lancet Oncol 8:55-62. 2007
    ..Invasive lobular carcinoma deserves to be investigated separately in prospective clinical trials to define the best treatment and prevention strategies...
  3. doi request reprint Assessment of quality of life in advanced non-small-cell lung cancer: an overview of recent randomized trials
    Everardo D Saad
    Dendrix Research, Sao Paulo, Brazil
    Cancer Treat Rev 38:807-14. 2012
    ..We assessed the frequency and correlates of both usage and gain in HRQOL endpoints in NSCLC phase III trials...
  4. pmc Bevacizumab as first-line therapy in advanced non-small-cell lung cancer: a brazilian center experience
    Denis Leonardo Fontes Jardim
    Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil
    Drugs R D 12:207-16. 2012
    ..A single Latin American center experience was reviewed to determine the safety and efficacy of adding bevacizumab to first-line chemotherapy in a local population...
  5. ncbi request reprint Trastuzumab: mechanisms of resistance and therapeutic opportunities
    Aknar Calabrich
    Oncology Center, Hospital Sirio Libanes, Sao Paulo, Brazil
    Oncology (Williston Park) 22:1250-8; discussion 1259, 1263. 2008
    ....
  6. ncbi request reprint Does neoadjuvant/adjuvant chemotherapy change the natural history of classic invasive lobular carcinoma?
    Artur Katz
    J Clin Oncol 23:6796; author reply 6796-7. 2005